《British Journal Of Cancer》雜志的最新年發(fā)文量為390篇。
這表明該刊在每年都會精選并發(fā)表一定數(shù)量的高質(zhì)量文章，以保持其在腫瘤學(xué)領(lǐng)域的學(xué)術(shù)影響力。
該刊聚焦于醫(yī)學(xué)-腫瘤學(xué)領(lǐng)域的前沿研究，致力于推動(dòng)該領(lǐng)域新技術(shù)和新知識的傳播與應(yīng)用。同時(shí)它積極鼓勵(lì)研究人員詳細(xì)發(fā)表其高質(zhì)量的實(shí)驗(yàn)研究和理論成果。
該刊的平均審稿周期約為 約6月 。
British Journal Of Cancer 雜志發(fā)文統(tǒng)計(jì)
文章名稱引用次數(shù)
- Mechanisms of resistance to immune checkpoint inhibitors159
- The fraction of cancer attributable to modifiable risk factors in England, Wales, Scotland, Northern Ireland, and the United Kingdom in 201569
- Cytokines in clinical cancer immunotherapy69
- Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer63
- Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-01262
- Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression58
- Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma50
- The clinical role of the TME in solid cancer43
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)37
- PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC36
國家/地區(qū)發(fā)文量
- England519
- USA422
- CHINA MAINLAND147
- GERMANY (FED REP GER)147
- Scotland135
- Italy128
- France122
- Australia108
- Japan103
- Canada86
